Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Axl

Axl

Brief Information

Name:AXL receptor tyrosine kinase
Target Synonym:EC:2.7.10.1,EC 2.7.10,UFO,AXL Transforming Sequence/Gene,AXL Oncogene,EC 2.7.10.1,JTK11,Tyro7,ARK,Tyrosine-protein kinase receptor UFO,AXL,AXL Receptor Tyrosine Kinase
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:21
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

AXL-H5253-ELISA
 Axl ELISA

Immobilized Human GAS6, His Tag (Cat. No. GA6-H5249) at 5 μg/mL (100 μL/well) can bind Human Axl, Fc Tag (Cat. No. AXL-H5253) with a linear range of 0.1-10 ng/mL (QC tested).

AXL-H82F9-MALS-HPLC
Biotinylated Human AXL, Fc,Avitag (Cat. No. ) MALS images

The purity of Biotinylated Human AXL, Fc,Avitag (Cat. No. AXL-H82F9) is more than 90% and the molecular weight of this protein is around 155-185 kDa verified by SEC-MALS.

Bioactivity-ELISA
Biotinylated Human AXL, Fc,AvitagBiotinylated Human AXL, Fc,Avitag (Cat. No. AXL-H82F9) ELISA bioactivity

Immobilized Human GAS6, His Tag (Cat. No. GA6-H5249) at 5 μg/mL (100 μL/well) can bind Biotinylated Human AXL, Fc,Avitag (Cat. No. AXL-H82F9) with a linear range of 1-31 ng/mL (QC tested).

Synonym Name

AXL,UFO

Background

AXL Receptor Tyrosine Kinase is also known as Tyrosine-protein kinase receptor UFO, which belongs to the protein kinase superfamily, Tyr protein kinase family and AXL/UFO subfamily. AXL contains two fibronectin type-III domains, two Ig-like C2-type (immunoglobulin-like) domains and one protein kinase domain. AXL is highly expressed in metastatic colon tumors. AXL is activated by GAS6-binding and subsequent autophosphorylation. AXL is involved in signal transduction from the extracellular matrix into the cytoplasm by binding growth factors, and thus implicated in the stimulation of cell proliferation.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Gilteritinib Fumarate ASP-2215; 66D-92MGC8M (UNII code); ASP-2215 hemifumarate Approved Astellas Pharma Inc Xospata Mainland China Leukemia, Myeloid, Acute Astellas Pharmaceutical (China) Co Ltd 2018-09-21 Solid tumours; Renal Insufficiency; Hepatic Insufficiency; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung Details
Cabozantinib S-malate XL-184; BMS-907351 Approved Exelixis Inc Cometriq, Cabometyx Japan Carcinoma, Renal Cell Takeda 2012-11-29 Osteosarcoma; Thyroid Neoplasms; Gliosarcoma; Colorectal Neoplasms; Peritoneal Neoplasms; Bile Duct Neoplasms; Hepatic Insufficiency; Astrocytoma; Breast Neoplasms; Sarcoma, Ewing; Lymphoma; Carcinoma, Adenosquamous; Adenocarcinoma, Clear Cell; Sarcoma, Clear Cell; Medullary thyroid cancer (MTC); Cholangiocarcinoma; Prostatic Neoplasms; Neurofibroma, Plexiform; Urethral Neoplasms; Carcinoma, Neuroendocrine; Meningioma; Carcinoma, Non-Small-Cell Lung; Paraganglioma; Melanoma; Carcinoma, Endometrioid; Thyroid Cancer, Papillary; Adenocarcinoma; Neoplasms, Germ Cell and Embryonal; Carcinoma, Hepatocellular; Neuroblastoma; Glioma; Leukemia, Myeloid, Acute; Carcinoma, Squamous Cell; Endometrial Neoplasms; Lung Neoplasms; Sarcoma, Alveolar Soft Part; Uterine Neoplasms; Fallopian Tube Neoplasms; Carcinoid Tumor; Neurofibromatoses; Seminoma; Carcinoma, Transitional Cell; Glioblastoma; Rejection of liver transplantation; Carcinoma, Merkel Cell; Hepatoblastoma; Pain; Pheochromocytoma; Neoplasms; Carcinoma, Renal Cell; B Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
NP-01 (Shijiazhuang No.4 Pharmaceutical/Nanjing Nadingfei Medical Technology) NP-01 Phase 1 Clinical Shijiazhuang No 4 Pharmaceutical Co Ltd, Nanjing Nadingfei Pharmaceutical Technology Co Ltd Liver Neoplasms; Solid tumours; Stomach Neoplasms; Lung Neoplasms Details
AGX-0073 AGX-0073 Phase 1 Clinical Shanghai Aojian Biological Technology Co Ltd Solid tumours Details
NP-107 NP107; NP-107 Phase 1 Clinical Shanghai Nawei Biotechnology Co Ltd Solid tumours Details
BPI-9016 BPI-9016; BPI-9016M Phase 1 Clinical Betta Pharmaceuticals Co Ltd Solid tumours; Carcinoma, Non-Small-Cell Lung Details
ONO-7475 ONO-7475 Phase 2 Clinical Ono Pharmaceutical Co Ltd Leukemia, Myeloid, Acute Details
Tilvestamab BGB-149 Phase 1 Clinical Bergenbio Ovarian Neoplasms Details
Enapotamab vedotin AXL-107-MMAE Phase 2 Clinical Seattle Genetics Inc, Genmab A/S Ovarian Neoplasms; Sarcoma; Endometrial Neoplasms; Thyroid Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma Details
XZB-0004 SLC-391; XZB-0004 Phase 1 Clinical Solid tumours; Hematologic Neoplasms; Foodborne Diseases; Carcinoma, Non-Small-Cell Lung Details
Butylidenephthalide HK-001; LF-001 (Everfront Biotech); NSC-325307; BDPH Phase 2 Clinical Everfront Biotech Co Ltd Glioma; Amyotrophic Lateral Sclerosis Details
Glesatinib 7Q29OXD98N; MG-90265H9; MG-90265gly; MG-90265; MG-90265X; MGCD-265 Phase 2 Clinical Mirati Therapeutics Inc Neoplasms; Carcinoma, Non-Small-Cell Lung Details
INCB-081776 INCB-81776; INCB-081776 Phase 1 Clinical Incyte Corp Solid tumours; Neoplasms Details
Dubermatinib TP-0903 Phase 2 Clinical Sumitomo Dainippon Ovarian Neoplasms; Solid tumours; Neoplasms; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Melanoma; Carcinoma, Non-Small-Cell Lung Details
Bemcentinib R-428; BGB-324 Phase 2 Clinical Rigel Pharmaceuticals Inc Coronavirus Disease 2019 (COVID-19); Inflammatory Breast Neoplasms; Triple Negative Breast Neoplasms; Myelodysplastic Syndromes; Adenocarcinoma of Lung; Pancreatic Neoplasms; Mesothelioma; Leukemia, Myeloid, Acute; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
KC1036 KC1036; KC-1036 Phase 2 Clinical Beijing Konruns Pharmaceutical Co Ltd Solid tumours; Hematologic Neoplasms; Digestive System Neoplasms; Neoplasm Metastasis Details
Q-702 Q-702 Phase 2 Clinical Qurient Co Ltd Solid tumours; Liver Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Neoplasm Metastasis; Uterine Cervical Neoplasms Details
FC-084-CSA FC-084-CSA; FC084CSA Phase 1 Clinical Zhongshan Yinuo Weishen New Drug Research and Development Co Ltd Solid tumours Details
PF-07265807 PF-07265807 Phase 1 Clinical Solid tumours; Neoplasm Metastasis Details
TT-00973 TT-00973 Phase 1 Clinical TransThera Sciences (Nanjing) Inc Solid tumours Details
HH-30134 HH-30134 Phase 1 Clinical ShangHai HaiHe Biopharma Co Ltd Solid tumours; Neoplasms Details
Ningetinib Tosylate CT-053-PTSA; CT-053 Phase 2 Clinical Hec Pharm Co Ltd Solid tumours; Intestinal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Lung Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung Details
CCT301-38 CCT301-38; CCT301-38 AXL Phase 2 Clinical F1 Oncology, Bioatla Carcinoma, Renal Cell; Rhinitis, Allergic, Seasonal Details
Mipasetamab uzoptirine ADCT-601; BGB-601 Phase 1 Clinical Adc Therapeutics Sa Solid tumours; Neoplasms Details
Mecbotamab vedotin BA-3011; BA3011; BA 3011 Phase 2 Clinical Bioatla Solid tumours; Leiomyosarcoma; Ovarian Neoplasms; Sarcoma, Synovial; Liposarcoma; Sarcoma; Osteosarcoma; Sarcoma, Ewing; Carcinoma, Non-Small-Cell Lung; Melanoma Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message